Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
Combined triglyceride-glucose index and body mass index for early cardiovascular risk stratification in adults under 45: Findings from the Kailuan cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Shuaiya, He Honghong, Liu Qian, Zhou Tong, Wang Yifan, Liu Nandi, Wang Dantong, Wu Yuntao, Chen Shuohua, Zu Changhao, Chen Lihua, Cui Kai, Zhao Haiyan
Аннотация
BACKGROUND AND AIM: Early-onset cardiovascular disease (CVD) in adults aged<45 years represents an increasing global health challenge. We aimed to evaluate the potential effects of the triglyceride-glucose (TyG) index and body mass index (BMI) on CVD risk in young adults.
METHODS AND RESULTS: We analyzed 65,291 CVD-free adults aged 18-44 years from the Kailuan Cohort (2006-2018). Participants were categorized by BMI (normal:<24 kg/m2; overweight:24-<28 kg/m2; obesity: ≥28 kg/m2) and TyG index (<8.45 vs ≥ 8.45). Cox proportional hazards models, interaction analyses, and ROC curves were applied. Over a median 7.2 years, 566 CVD events occurred. Obesity was associated with higher CVD risk regardless of TyG (obesity + TyG <8.45: HR = 1.55; 95%CI = 1.03-2.34; obesity + TyG ≥8.45: HR = 1.64; 95%CI = 1.23-2.18). Overweight participants showed increased risk only when TyG ≥8.45 (HR = 1.37; 95%CI = 1.05-1.79), whereas metabolically healthy overweight individuals (TyG <8.45) had no excess risk. Normal-weight participants with high TyG did not exhibit a significant risk increase (HR = 1.13; 95%CI = 0.84-1.53). No significant additive or multiplicative interaction between BMI and TyG was observed. Predictive performance improved when both measures were combined (0.623) compared with BMI (0.587) or TyG (0.601) alone (P < 0.001).
CONCLUSIONS: The combined assessment of TyG and BMI may facilitate early risk stratification and enhance risk awareness for CVD in adults aged<45 years. Obesity remains a high-risk phenotype regardless of metabolic status, whereas overweight confers increased risk only in metabolic dysfunction. This integrated approach supports a tiered prevention strategy: prioritizing weight management in obesity, targeting metabolic dysfunction in overweight individuals, and monitoring normal-weight individuals with elevated TyG for long-term risk.
METHODS AND RESULTS: We analyzed 65,291 CVD-free adults aged 18-44 years from the Kailuan Cohort (2006-2018). Participants were categorized by BMI (normal:<24 kg/m2; overweight:24-<28 kg/m2; obesity: ≥28 kg/m2) and TyG index (<8.45 vs ≥ 8.45). Cox proportional hazards models, interaction analyses, and ROC curves were applied. Over a median 7.2 years, 566 CVD events occurred. Obesity was associated with higher CVD risk regardless of TyG (obesity + TyG <8.45: HR = 1.55; 95%CI = 1.03-2.34; obesity + TyG ≥8.45: HR = 1.64; 95%CI = 1.23-2.18). Overweight participants showed increased risk only when TyG ≥8.45 (HR = 1.37; 95%CI = 1.05-1.79), whereas metabolically healthy overweight individuals (TyG <8.45) had no excess risk. Normal-weight participants with high TyG did not exhibit a significant risk increase (HR = 1.13; 95%CI = 0.84-1.53). No significant additive or multiplicative interaction between BMI and TyG was observed. Predictive performance improved when both measures were combined (0.623) compared with BMI (0.587) or TyG (0.601) alone (P < 0.001).
CONCLUSIONS: The combined assessment of TyG and BMI may facilitate early risk stratification and enhance risk awareness for CVD in adults aged<45 years. Obesity remains a high-risk phenotype regardless of metabolic status, whereas overweight confers increased risk only in metabolic dysfunction. This integrated approach supports a tiered prevention strategy: prioritizing weight management in obesity, targeting metabolic dysfunction in overweight individuals, and monitoring normal-weight individuals with elevated TyG for long-term risk.